Options for MRD Testing Affect Patient Treatment Plan in Lung Cancer
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.
Related Articles
Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising
Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.
A Pioneering Journey in Radiation Oncology Inspired by Multidisciplinary Collaboration
Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.
New Advances in Waldenström Macroglobulinemia
Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.
Debate: What Is the Best Posttransplant Follow-Up – Maintenance vs Close Monitoring With Laboratory Testing
Panelists debate the best posttransplant follow-up approach for acute myeloid leukemia, weighing the benefits of maintenance therapy vs close monitoring with regular laboratory testing to…
Ohio State’s Update From the 2024 San Antonio Breast Cancer Symposium 02/01/2025
Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2024 San Antonio…
Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC
Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
